Analysts’ new coverage for Monday, August 31st:
Leerink Partners assumed coverage on shares of Attovia Therapeutics (NASDAQ:ATTO). Leerink Partners issued an outperform rating and a $52.00 target price on the stock.
Citigroup Inc. started coverage on shares of Attovia Therapeutics (NASDAQ:ATTO). They issued a buy rating and a $30.00 target price on the stock.
Morgan Stanley started coverage on shares of Attovia Therapeutics (NASDAQ:ATTO). Morgan Stanley issued an overweight rating and a $39.00 price target on the stock.
Lifesci Capital assumed coverage on shares of Attovia Therapeutics (NASDAQ:ATTO). Lifesci Capital issued an outperform rating and a $45.00 target price on the stock.
Cantor Fitzgerald started coverage on shares of Braveheart Bio (NASDAQ:BRVE). The firm issued an overweight rating and a $40.00 target price on the stock.
Stifel Nicolaus started coverage on shares of Braveheart Bio (NASDAQ:BRVE). They issued a buy rating and a $45.00 target price on the stock.
Needham & Company LLC began coverage on shares of Babcock (NYSE:BW). The firm issued a buy rating and a $20.00 price target on the stock.
Maxim Group initiated coverage on shares of Deep Fission (NASDAQ:FISN). They issued a buy rating and a $17.00 target price on the stock.
B. Riley Financial, Inc. initiated coverage on shares of Gorilla Technology Group (NASDAQ:GRRR). They issued a buy rating and a $25.00 target price on the stock.
Rodman & Renshaw began coverage on shares of Quantum Biopharma (NASDAQ:QNTM). They issued a buy rating and a $8.00 target price on the stock.
Evercore Inc initiated coverage on shares of Red Cat (NASDAQ:RCAT). They issued an outperform rating and a $15.00 price target on the stock.
Stephens began coverage on shares of River City Bank (NASDAQ:RCBC). Stephens issued an equal weight rating and a $54.00 target price on the stock.
Raymond James Financial, Inc. started coverage on shares of River City Bank (NASDAQ:RCBC). They issued an outperform rating and a $56.00 target price on the stock.
DA Davidson assumed coverage on shares of River City Bank (NASDAQ:RCBC). The firm issued a neutral rating and a $55.00 price target on the stock.
HC Wainwright assumed coverage on shares of Scribe Therapeutics (NASDAQ:SCTX). The firm issued a buy rating and a $60.00 target price on the stock.
Receive News & Ratings for Attovia Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Attovia Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
